Related Experiment Video
Updated: Aug 4, 2025
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Targeting PD-1/PD-L1 in biliary tract cancer: role and available data
Reem D Mahmood1, Kathryn Graham2, Jack Gleeson1
1Department of Medical Oncology, Christie NHS Foundation Trust, Manchester, M20 4BX, UK.
Abstract:
There is a critical need for novel therapies to treat patients with advanced biliary tract cancer (BTC). This systematic review summarizes the evidence-based knowledge for the potential role of PD-1 and PD-L1 monoclonal antibodies in the treatment of patients with early-stage and advanced BTC. An Embase database search was conducted, identifying 15 eligible phase II/III clinical trials for review. Results from recent phase III trials show a statistically significant overall survival (OS) benefit from the addition of PD-1/PD-L1 inhibitors to chemotherapy in the first-line management of advanced BTC. Future research should concentrate on the discovery of biomarkers to identify patients who would benefit most from these therapies.
Insights
Novel therapies, including PD-1/PD-L1 inhibitors, show survival benefits for advanced biliary tract cancer (BTC). Further research is needed to identify biomarkers for optimal patient selection in BTC treatment.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Biliary tract cancer (BTC) requires novel therapeutic strategies, particularly for advanced stages.
- Immune checkpoint inhibitors targeting PD-1 and PD-L1 represent a promising avenue for BTC treatment.
Approach:
- A systematic review of 15 phase II/III clinical trials was conducted using the Embase database.
- Evidence regarding the efficacy of PD-1 and PD-L1 monoclonal antibodies in early-stage and advanced BTC was synthesized.
Key Points:
- First-line treatment combining chemotherapy with PD-1/PD-L1 inhibitors demonstrated a statistically significant overall survival benefit in advanced BTC.
- These findings highlight the potential of immunotherapy in improving outcomes for patients with advanced BTC.
Conclusions:
- PD-1/PD-L1 inhibitors are a valuable addition to chemotherapy for advanced BTC, improving overall survival.
- Future research should focus on identifying predictive biomarkers to personalize immunotherapy selection for BTC patients.
